What TOM Patients Can Expect from the TrumpRX News
TOM Weight Loss and the New TrumpRx Opportunity
At TOM Weight Loss we continually monitor major shifts in the obesity-medication space so we can keep our patients informed and positioned to benefit. A significant development has just arrived: the launch of the TrumpRx-channel pricing agreements for name-brand GLP-1 medications. This creates a new route for patients who prefer a brand-name, FDA-approved therapy and desire predictable pricing.
To summarise the key pricing announcements:
• Under the agreement announced Nov. 6, 2025, the average monthly cost for injectable GLP-1 medications purchased via TrumpRx will start at approximately
$350/month and is expected to trend down toward
$245/month over the next couple of years. (The White House)
• For patients in Medicare or Medicaid (or coverage via models derived from the agreement), the negotiated price for the same injectable GLP-1s is stated to be
$245/month and the copay for a Medicare beneficiary is capped at
$50/month. (NCPA)
• Specifically for brand-name Zepbound (from Eli Lilly and Company), the lowest dose for self-pay cash patients is cited at
$299/month, with higher doses capped at
$449/month under the newly announced framework. (Reuters)
• For brand-name Wegovy (from Novo Nordisk), the cash price has been reduced to
$349/month for the full dose and an introductory offer of
$199/month for the first two months of the lowest doses. (Reuters)
In plain language: once TrumpRx is fully operational, patients paying cash rather than using standard commercial insurance may access Wegovy for ~$349/month (or $199/month initially for certain doses), and Zepbound at ~$299–$449/month depending on dose. Patients covered by Medicare/Medicaid may see a net cost of ~$245/month (with ~$50 copay). These are substantial reductions compared to previous direct-to-consumer pricing in excess of $500/month or more. (STAT)
At TOM Weight Loss we are pleased to announce that once the TrumpRx website is live and operational, we will be happy to prescribe through it for eligible patients who prefer the brand-name route. Our team will coordinate with you to determine eligibility, do the necessary evaluation, and help you transition to that channel if it works for your situation.
That said, this development does not mean compounded options are obsolete. There remain patients for whom compounded medications, such as generic-equivalent formulations of Semaglutide or Tirzepatide, continue to be the better medical choice. For example:
- A patient may experience intolerable side-effects on the brand formulation (e.g., injection-site reactions, nausea, supply delays) and require a more flexible, compounded regimen.
- A patient may have special dose-adjustment needs (micro-dosing, titration) that the brand product’s fixed dosing schedule makes awkward.
Thus, at TOM Weight Loss we will maintain both pathways: brand-name through TrumpRx, or other pharmacies, when operational and clinically appropriate, and compounded formulations when medically indicated or more favorable from a tolerance standpoint.
We view the new TrumpRx pricing as a valuable addition to our menu of options. As always, the choice of therapy will turn on the individual patient’s clinical profile, side-effect tolerability, and personal preferences—our role is to help you navigate those factors.
Click here if you want to get started today!
This post is not medical advice. Please consult a doctor before making any healthcare decisions.
Please review and let me know if you would like any modulations in tone, further detail (e.g., side-effect profiles, comparative dosing) or additional segments for your email campaign.
